CA2331318A1 - Compositions comprising 2-phenyl-indole compounds and estrogen formulations - Google Patents
Compositions comprising 2-phenyl-indole compounds and estrogen formulations Download PDFInfo
- Publication number
- CA2331318A1 CA2331318A1 CA002331318A CA2331318A CA2331318A1 CA 2331318 A1 CA2331318 A1 CA 2331318A1 CA 002331318 A CA002331318 A CA 002331318A CA 2331318 A CA2331318 A CA 2331318A CA 2331318 A1 CA2331318 A1 CA 2331318A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- alkyl
- estrogens
- hydroxy
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1c(cc(*)cc2)c2N(CI2=C=C=C(*)C=C2)C1c1cc(*)c(*)cc1 Chemical compound *C1c(cc(*)cc2)c2N(CI2=C=C=C(*)C=C2)C1c1cc(*)c(*)cc1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7960498A | 1998-05-15 | 1998-05-15 | |
US7964498A | 1998-05-15 | 1998-05-15 | |
US09/079,604 | 1998-05-15 | ||
US09/079,644 | 1998-05-15 | ||
PCT/US1999/010215 WO1999059969A1 (en) | 1998-05-15 | 1999-05-11 | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2331318A1 true CA2331318A1 (en) | 1999-11-25 |
Family
ID=26762198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002331318A Abandoned CA2331318A1 (en) | 1998-05-15 | 1999-05-11 | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1080073A1 (de) |
JP (1) | JP2002515484A (de) |
CN (1) | CN1309637A (de) |
AU (1) | AU3894299A (de) |
CA (1) | CA2331318A1 (de) |
WO (1) | WO1999059969A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1990051A1 (de) * | 2000-07-06 | 2008-11-12 | Wyeth | Kombinationen aus SSRI und Östrogenmitteln |
CN1468110A (zh) * | 2000-07-06 | 2004-01-14 | 惠氏公司 | 他汀类、雌激素药物以及任选雌激素的联合应用 |
EP1656938A1 (de) * | 2000-07-06 | 2006-05-17 | Wyeth | Kombinationen aus SSRI und Oestrogenmitteln |
WO2002003989A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
US6376486B1 (en) | 2000-07-06 | 2002-04-23 | American Home Products Corporation | Methods of inhibiting sphincter incontinence |
EP1299093A2 (de) * | 2000-07-06 | 2003-04-09 | Wyeth | Kombinationen aus bisphosphonaten, östrogenmitteln und gegebenenfalls östrogenen |
US6455568B2 (en) | 2000-07-06 | 2002-09-24 | Wyeth | Combination therapy for inhibiting sphincter incontinence |
WO2002003992A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
JP2004524354A (ja) * | 2001-03-16 | 2004-08-12 | ワイス | エストロゲン補充療法 |
DE10117441A1 (de) * | 2001-04-03 | 2002-10-10 | Schering Ag | 1-Indolylderivate, deren Verwendung zur Herstellung von Arzneimitteln, ein Verfahren zur Herstellung der 1-Indolylderivate sowie 1-Indolylderivate enthaltende pharmzeutische Präparate |
WO2002094268A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
WO2002094788A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
CA2448235A1 (en) | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
US20040002604A1 (en) | 2001-12-10 | 2004-01-01 | Richard Apodaca | Phenylalkynes |
EA200400661A1 (ru) | 2001-12-10 | 2004-12-30 | Орто-Макнейл Фармасьютикал, Инк. | Фенилалкины |
BR0316971A (pt) * | 2002-12-02 | 2005-10-25 | Ortho Mcneil Pharm Inc | Fenilalquinas |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CN104098499B (zh) * | 2013-04-08 | 2016-05-04 | 上海医药工业研究院 | 5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1h-吲哚的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH30747A (en) * | 1989-03-10 | 1997-10-17 | Endorech Inc | Combination therapy for the treatment of estrogen sensitive disease. |
CA2135160A1 (en) * | 1992-05-08 | 1993-11-25 | Masatoshi Inai | Indole derivative |
DE4335876A1 (de) * | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
JP3536258B2 (ja) * | 1994-02-22 | 2004-06-07 | メレルファーマスーティカルズ インコーポレイテッド | エストロゲンに関連する新生物及び病気の処置に有用な新規なインドール誘導体類 |
DE4426625A1 (de) * | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
US5552401A (en) * | 1995-02-28 | 1996-09-03 | Eli Lilly And Company | 2-benzyl-3-arylbenzothiophenes |
EP0802183B1 (de) * | 1996-04-19 | 2001-10-10 | American Home Products Corporation | Östrogene Verbindungen |
TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
-
1999
- 1999-05-11 CA CA002331318A patent/CA2331318A1/en not_active Abandoned
- 1999-05-11 WO PCT/US1999/010215 patent/WO1999059969A1/en not_active Application Discontinuation
- 1999-05-11 EP EP99921832A patent/EP1080073A1/de not_active Withdrawn
- 1999-05-11 JP JP2000549588A patent/JP2002515484A/ja active Pending
- 1999-05-11 CN CN99808648A patent/CN1309637A/zh active Pending
- 1999-05-11 AU AU38942/99A patent/AU3894299A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1080073A1 (de) | 2001-03-07 |
JP2002515484A (ja) | 2002-05-28 |
WO1999059969A1 (en) | 1999-11-25 |
AU3894299A (en) | 1999-12-06 |
CN1309637A (zh) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0802184B1 (de) | N-Benzyl-2-phenylindole als östrogene Mittel | |
US5780497A (en) | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents | |
US5880137A (en) | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents | |
US8815934B2 (en) | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | |
AU760378B2 (en) | 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole in combination with estrogens | |
US5985910A (en) | 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents | |
US6583170B1 (en) | 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations | |
CA2331318A1 (en) | Compositions comprising 2-phenyl-indole compounds and estrogen formulations | |
US6159959A (en) | Combined estrogen and antiestrogen therapy | |
CA2203079C (en) | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents | |
MXPA00011170A (en) | Compositions comprising 2-phenyl-indole compounds and estrogen formulations | |
EP1082319B1 (de) | Benzocarbazol und indenoindole derivate als östrogene agentien | |
CA2203074A1 (en) | Estrogenic agents | |
CA2203073A1 (en) | Estrogenic agents | |
MXPA00011178A (en) | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens | |
MXPA97002866A (en) | Estrogeni agents | |
MXPA00011087A (en) | Benzocarbazole and indenoindole derived estrogenic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |